Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinical signs and symptoms of VL and confirmatory parasitological microscopic diagnosis~* Patients aged \> 4 to \< 12 years who are able to comply with the study protocol.~* Patients for whom written informed consent has been signed by parents(s) or legal guardian~* Weight \< 30 kg~Exclusion Criteria:~* Patients who are relapse cases~* Patients who have received any anti-leishmanial drugs in the last 6 months~* Patients with severe malnutrition (for children aged \<5 years, weight-for-height WHO reference curves by gender, z score \<-3; for children 5-12 years, BMI-for-age WHO reference curves for gender, z score \< -3)~* Patients with positive HIV diagnosis~* Patients with previous history of hypersensitivity reaction to miltefosine~* Patients suffering from a concomitant severe infection such as Tuberculosis (TB) or any other serious underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the patient's response to study medication~* Patients suffering from other conditions associated with splenomegaly such as schistosomiasis~* Pregnant or lactating women or female patient in childbearing age (reached menarche)~* Patients with haemoglobin \< 5g/dl~* Patients with White Blood Cells (WBC) \< 1 x 10³/mm³~* Patients with platelets \< 40,000/mm³~* Patients with abnormal liver function (ALT and AST) tests of more than three times the normal range.~* Patients with bilirubin more than 1.5 times the upper normal range~* Patients with serum creatinine above the upper limit of normal (ULN) for age and gender.~* Patients with clinical signs of severe VL disease such as jaundice and bleeding~* Patients who cannot comply with the planned scheduled visits and procedures of the study protocol

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Miltefosine (Type: EXPERIMENTAL): allometric dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).